Michael Trauner

, Austria


Chair(s)

Part 2 chair - Research Think Tank - Autoimmune and cholestatic liver diseases
Workshop
10 April 2019 08:00 - 11:00 More ...
Chair - Parallel session: Autoimmune and cholestasis I
Science/Research
11 April 2019 16:00 - 18:00 More ...
Chair - Pros & Cons Session: PBC patients with inadequate response to UDCA: obeticholic acid or bezafibrate?
Workshop
14 April 2019 10:30 - 11:30 More ...
Chair - Meet the Experts: Management of non response to therapy in PBC patients
Meet the Experts
14 April 2019 09:30 - 10:20 More ...

Presentations

Shared mechanisms in cholestatic and fatty liver disease - implications for current and future treatment 12 April 2019 10:30 - 11:00 More ...
Methylation signatures in blood show accelerated epigenetic aging in patients with primary sclerosing cholangitis compared to healthy controls 11 April 2019 09:00 - 19:00 More ...

Abstracts

Glucagon like peptide-2 treatment improves liver and bile duct injury in the Mdr2-/- mouse model of sclerosing cholangitis Autoimmune and chronic cholestatic liver disease: Experimental and pathophysiology More
Absence of BSEP (ABCB11) protects MDR2 (ABCB4) KO mice from cholestatic liver and bile duct injury through anti-inflammatory bile acid composition and signaling Autoimmune and chronic cholestatic liver disease: Experimental and pathophysiology More
Loss of bile salt export pump (Bsep/Abcb11) aggravates lipopolysaccharide induced hepatic inflammation in mice Autoimmune and chronic cholestatic liver disease: Experimental and pathophysiology More